Application YC di Altay Therapeutics

Winter 2020Active

Altay Therapeutics ha partecipato a Y Combinator nel batch Winter 2020 come azienda Healthcare. Sotto: cosa fa l'azienda, chi l'ha fondata e la sua application a YC, ricostruita domanda per domanda nel form reale di YC.

Batch YC: Winter 2020
Settore: HealthcareTherapeutics
Dimensione team: 6
Stato: Active
Lanciata: 2020

Founder

Ali OzesFounder
Osman OzesFounder

Cosa fa Altay Therapeutics

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Application YC di Altay Therapeutics, ricostruita

Domanda per Y Combinator

Altay Therapeutics, batch Winter 2020. Le vere domande del form, risposte da dati pubblici.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Altay Therapeutics

Describe what your company does in 50 characters or less.

Small molecule therapies for liver disease

What is your company going to make? Please describe your product and what it does or will do.

We develop small molecule drugs that target transcription pathways to treat chronic liver diseases like fibrosis and cancer. Our lead compound has shown in mouse models not just reduction but reversal of liver fibrosis, aiming for a clinic-ready drug by end of 2021 and phase I trials mid-2022.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, which will remain our base after YC.

Explain your decision regarding location.

We chose to base the company in San Francisco because that's where the biotech innovation ecosystem and our team are. It keeps us close to partners, investors, and talent relevant to small molecule therapeutic development.

21 risposte in più nell'application completa

Founders, Progress, Idea, Equity, Curious, Batch Preference sono nella versione completa. Crea un account gratuito per aprirla in YC Insights, accanto a ogni altro batch YC.

Vedi domanda completa

Domande Frequenti

Questa è l'application YC reale di Altay Therapeutics?

No. Y Combinator mantiene private le application inviate. Questa è una ricostruzione: le domande del form YC reale, a cui si è risposto usando i dati pubblici di Altay Therapeutics (note di lancio, background dei founder, descrizione del prodotto). Mostra come un'azienda come Altay Therapeutics si presenterebbe a YC, non il testo che hanno inviato.

A quale batch YC apparteneva Altay Therapeutics?

Altay Therapeutics apparteneva al batch Winter 2020 di Y Combinator.

Chi ha fondato Altay Therapeutics?

Altay Therapeutics è stato fondato da Ali Ozes, Osman Ozes.

Cosa fa Altay Therapeutics?

Altay develops disease-modifying therapies targeting transcription…

Come leggo la ricostruzione completa della application?

Crea un account Round Funded gratuito. La versione completa di 26 risposte della application di Altay Therapeutics, e di ogni altro batch YC, è in YC Insights.